The Nitric Oxide (NO) Donor Sodium Nitroprusside (SNP) and Its Potential for the Schizophrenia Therapy: Lights and Shadows
Open Access
Abstract
Schizophrenia is a severe psychiatric disorder affecting up to 1% of the worldwide population. Available therapy presents different limits comprising lack of efficiency in attenuating negative symptoms and cognitive deficits, typical features of schizophrenia and severe side effects. There is pressing requirement, therefore, to develop novel neuroleptics with higher efficacy and safety. Nitric oxide (NO), an intra- and inter-cellular messenger in the brain, appears to be implicated in the pathogenesis of schizophrenia. In particular, underproduction of this gaseous molecule is associated to this mental disease. The latter suggests that increment of nitrergic activity might be of utility for the medication of schizophrenia. Based on the above, molecules able to enhance NO production, as are NO donors, might represent a class of compounds candidates. Sodium nitroprusside (SNP) is a NO donor and is proposed as a promising novel compound for the treatment of schizophrenia. In the present review, we intended to critically assess advances in research of SNP for the therapy of schizophrenia and discuss its potential superiority over currently used neuroleptics.Keywords
This publication has 74 references indexed in Scilit:
- Nitric Oxide Donors as Neuroprotective Agents after an Ischemic Stroke-Related Inflammatory ReactionOxidative Medicine and Cellular Longevity, 2013
- Targeting glutamate synapses in schizophreniaTrends in Molecular Medicine, 2011
- Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRIPsychiatry Research: Neuroimaging, 2011
- Oxidative stress in schizophrenia: An integrated approachNeuroscience & Biobehavioral Reviews, 2011
- Hyperdopaminergic Tone Erodes Prefrontal Long-Term Potential via a D2Receptor-Operated Protein Phosphatase GateJournal of Neuroscience, 2009
- Cingulate White Matter Neurons in Schizophrenia and Bipolar DisorderBiological Psychiatry, 2009
- Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controlsSchizophrenia Research, 2008
- Recent developments in nitric oxide donor drugsBritish Journal of Pharmacology, 2007
- Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide productionNeuroscience Letters, 1996
- Nitric oxide: A cytotoxic activated macrophage effector moleculeBiochemical and Biophysical Research Communications, 1988